Sterile drug manufacturing faces tighter contamination controls as India proposes WHO-aligned microbial limits, placing cleanroom monitoring and pharmaceutical quality assurance under greater scrutiny.
Sino Biopharmaceutical’s USD 7 billion oncology agreement highlights preclinical oncology licensing and the company's expanding strategy of partnering its drug pipeline with global pharmaceutical groups.
Nurix loses a potential USD 455 million milestone opportunity after Sanofi discontinues its STAT6 degrader programme, raising questions about targeted protein degradation in autoimmune drug development.
Teva raises its 2026 outlook as branded medicines gain ground, with Austedo, Ajovy and Uzedy strengthening earnings despite generics pressure.
Kapiva takes science-backed Ayurveda into Cult Neo’s fitness ecosystem, expanding natural wellness, nutrition, and recovery support across 250 gyms nationwide.
Wockhardt seeks 14-year regulatory data protection for local drug research, raising questions about innovation incentives, regulatory delays, and patient access.
BioMerieux's latest results highlight how pharma quality control, mycoplasma testing and advanced microbiological solutions are becoming important drivers of growth in industrial diagnostics.
Novartis' pelacarsen setback puts Lp(a) screening in India under focus, highlighting inherited cholesterol risks, preventive testing and gaps in cardiovascular risk assessment in Indian healthcare.
Cerus' Phase 3 success advances Blood Safety research, raising questions about pathogen reduction's potential role in strengthening India's blood transfusion infrastructure and preparedness.
Center expands drug import gateways under Rule 43A, aiming to ease pharma logistics, improve cargo movement and reduce clearance delays.
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")
